greeksoup/ stock research

Rapid Micro Biosystems, Inc.: Q3 FY2026 earnings call

What management said about Q3 FY2026, from the documents filed with the SEC on 16 November 2026: press release. The quarter’s numbers.

Key takeaways

  • Revenue rose 22% on both lines: Total revenue was $9.5 million, up 21.6% from $7.8 million. Management said growth came from both product and service businesses. Source
  • Adjusted EBITDA loss narrowed: Non-GAAP adjusted EBITDA loss was $7.9 million, against $9.4 million a year earlier. Source
  • Gross margin reached 25.2%: Gross margin was 25.2%, or $2.4 million, against 8.9%, or $0.7 million, a year earlier. The company called it a quarterly record. Source
  • Cash about $7 million at quarter-end: Cash, cash equivalents and short-term investments were about $7 million at September 30, 2026, against about $20 million at June 30, 2026 in the prior release. Source
  • Definitive agreement to be acquired: The company signed a definitive agreement under which Merck KGaA, Darmstadt, Germany, has agreed to acquire all outstanding shares, subject to agreement terms. Source
  • Form 10-Q filing delayed: The company will delay its Form 10-Q for the quarter ended September 30, 2026, citing added time for reporting and disclosure tied to the acquisition. Source

“We are pleased to report 22% third quarter total revenue growth driven by both our Product and Service businesses,”

Rob Spignesi, President and CEO

What changed from last quarter

  • New: Definitive agreement signed for Merck KGaA, Darmstadt, Germany to acquire all outstanding shares of the company. Source
  • Guidance withdrawn: Full-year 2026 guidance withdrawn. The prior release had reaffirmed revenue of $37.0 million to $41.0 million, 30 to 38 placements, about 20% gross margin, and at least 27 validations. Source
  • Ended: No conference call on third-quarter 2026 results, unlike the prior quarter's call. Source
  • New: Focused efficiency program announced in August 2026, with a restructuring charge recorded in the third quarter. Source
  • New: Non-GAAP adjusted EBITDA definition now also excludes restructuring, which the prior release's definition did not. Source

Results and growth drivers

  • Revenue rose 22% on both lines: Total revenue was $9.5 million, up 21.6% from $7.8 million. Management said growth came from both product and service businesses. Source
  • Net loss narrowed to $11.3 million: Net loss was $11.3 million, or $0.23 per share, against $11.5 million, or $0.26 per share, a year earlier. Source
  • Adjusted EBITDA loss narrowed: Non-GAAP adjusted EBITDA loss was $7.9 million, against $9.4 million a year earlier. Source

Product and service revenue

  • Product revenue up 24.9%: Product revenue was $6.5 million, up 24.9%, and grew faster than service revenue this quarter. Source
  • Service revenue up 14.9%: Service revenue was $3.0 million, up 14.9% from $2.6 million. Source
  • Recurring revenue up 6.9%: Recurring revenue was $5.2 million, up 6.9%, after 14.3% growth reported for the second quarter. Source

“I am also particularly pleased with the continued progress in our gross margin expansion initiatives, which resulted in a third quarter total gross margin of 25%, including record Product and Service gross margins.”

Rob Spignesi, President and CEO

Placements and validations

  • Seven Growth Direct placements: Seven new Growth Direct systems were placed, against five in the third quarter of 2025. Source
  • Twelve customer validations completed: Validation of 12 customer systems was completed, against four in the third quarter of 2025. Source
  • Validations exceeded placements: Validations (12) were above placements (7) this quarter. The second-quarter release reported four placements and nine validations. Source

Operating costs

  • Cost of revenue held flat: Total cost of revenue was $7.1 million, unchanged from the same quarter of 2025, while revenue rose. Source
  • Operating expenses up 8.1%: Operating expenses were $13.0 million, up 8.1% from $12.1 million, including the restructuring charge. Source
  • G&A up, R&D down: General and administrative costs rose 12.2% and sales and marketing rose 4.3%, while research and development fell 15.8%. Source
  • Restructuring charge of $0.7 million: A non-recurring $0.7 million restructuring charge is included in operating expenses, linked to the August 2026 efficiency program. Source

“We are confident that joining the Life Science business of Merck KGaA, Darmstadt, Germany will significantly expand the Growth Direct's reach, accelerate adoption of the Growth Direct platform and more fully serve our combined global customer base.”

Rob Spignesi, President and CEO

Gross margin and margin initiatives

  • Gross margin reached 25.2%: Gross margin was 25.2%, or $2.4 million, against 8.9%, or $0.7 million, a year earlier. The company called it a quarterly record. Source
  • Product and service margins rose: Product gross margin was 12%, up 19 points. Service gross margin was 54%, up 14 points, against the third quarter of 2025. Source
  • Margin initiatives credited: Management credited gross margin expansion initiatives for the 25% total gross margin and cited continued progress on them. Source

Cash and balance sheet

  • Cash about $7 million at quarter-end: Cash, cash equivalents and short-term investments were about $7 million at September 30, 2026, against about $20 million at June 30, 2026 in the prior release. Source
  • Notes payable and equity lower: Notes payable, net, were $19.2 million and total stockholders' equity was $8.8 million, against $33.2 million at December 31, 2025. Source
  • Payables and deferred revenue: Accounts payable were $4.8 million and deferred revenue $4.4 million, against $4.1 million and $4.7 million at December 31, 2025. Source

Merck acquisition and reporting

  • Definitive agreement to be acquired: The company signed a definitive agreement under which Merck KGaA, Darmstadt, Germany, has agreed to acquire all outstanding shares, subject to agreement terms. Source
  • Eighteen-month partnership cited: Management described an 18-month partnership with Merck KGaA, centred on innovation and modernizing customer quality-control workflows. Source
  • Offer not yet launched: The company states the tender offer has not commenced and that the release is neither an offer to purchase nor a solicitation. Source
  • No earnings call this quarter: No conference call on third-quarter results will be held, given the acquisition announcement. Source
  • Form 10-Q filing delayed: The company will delay its Form 10-Q for the quarter ended September 30, 2026, citing added time for reporting and disclosure tied to the acquisition. Source

Coming up, as management said on 16 November 2026

  • Tender offer filings to follow: When the offer is commenced, Merck and its purchaser will file a Schedule TO, and Rapid will file a Schedule 14D-9. Source
  • Form 10-Q within extension period: Management intends to file the Form 10-Q within the extension period permitted under Rule 12b-25. Source

Figures management reported

FigureReported
Growth Direct system placements, third quarter Source7 (5 in third quarter 2025)
Customer systems validated, third quarter Source12 (4 in third quarter 2025)

Risks management discussed

  • Regulatory: Form 10-Q filing delayed because added time is needed for financial reporting and disclosure matters tied to the acquisition. Source

Earlier plans management reported on

  • Not stated: The $0.7 million restructuring charge relates to the program. The release gives no progress report on the program. Source
  • Not stated: Management referred to continued progress on gross margin expansion initiatives, without a stated target or timing. Source

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.